Please login to the form below

Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and flawless execution.

We are an uncommon health communications agency with a deep understanding of today’s complex healthcare environment.

Providing smart thinking, refreshing storytelling, and breakthrough solutions: from strategies through to entire campaigns.

We pioneer new routes and break new ground to deliver breakthroughs for our clients.

PharmaTimes Award Winners 2019: International Challenge

EMEA Sabre Award Winners 2019: Medical Technology

PRWeek Award Winners 2019: Issues and Reputation Management

Find out more at www.hanovercomms.com

Press Releases

Will the NHS be safe in Liz Truss’s Hands?

As expected, Liz Truss has been anointed as the new Prime Minister. One of her major challenges is the NHS and, with only two years to another general election, she does not have much time to restore falling public confidence in the service.

A new prescription for the U.S. healthcare market?

Last month the U.S. Government passed the Inflation Reduction Act, paving the way for unprecedented drug pricing reforms across the country. In a market with spiralling healthcare costs, and increasing stories of patients missing out, or rationing treatment, the Act is welcomed by many. But it’s also severely criticised by others, including representatives from the pharmaceutical industry who say it jeopardises future innovation and drug discovery. As the largest pharmaceuticals market, the impact of the legislation will be felt outside of the U.S., but what does this look like, in the short and long-term? Is it a proverbial drop in the ocean, or is a storm brewing?

What's next for the 'indispensable' health system?
No one is remotely indispensable” – those of the words many of us have heard these past few weeks. As Boris Johnson and the previously incumbent Cabinet are now considering their next moves, where does that leave health policy at one of the most volatile points in recent history? We were set for a bumper few months of hotly anticipated announcements, including the 10-Year Cancer  Plan response, the Women’s Health Strategy, and the implementation plan for the Life Sciences Vision, amongst many others. But what will happen as the forthcoming leadership contest dominates the column inches? How will the Civil Service and NHS stand up to the challenges it faces without certainty of who is steering the ship? We will explore some of the possibilities of what will happen next, and most importantly, how we in communications can support the health system at such a critical time post-pandemic. To find out, read the latest blog on the PM Hub, penned by Hanover Health's Senior Account Director Ursula Ritz.
How can the UK be a catalyst for change in women’s health? 

Women’s health has once again been thrust to the fore, with almost daily stories on hormone replacement therapy (HRT) supply shortages in the UK providing us with a stark reminder of the challenges women are facing in this country every day. The good news is, the UK Government is making a genuine and concerted effort to tackle women’s health issues, having set out its Vision for women’s health in December, and a full Strategy due to be published imminently. We have a real opportunity to change women’s experience of healthcare for the better, but we cannot afford to get this wrong. In her latest blog, Hanover’s Georgia Hunt explores how the upcoming Women’s Health Strategy should address the concerns of women today and improve the lives of the women of tomorrow.

Innovative contracting at the top of the market access agenda

Value-based contracting (VBC) is firmly on the market access agenda across Europe and there are converging views on what is needed in this space.  Pharma and biotech, patients, payers, regulators and HTA agencies gathered at the World Evidence, Pricing and Access Congress in March to discuss challenges and potential solutions. Hanover hosted a discussion about experiences of VBC and where changes are needed. We explored whether a global archetype approach could support in-country negotiating agreements.   In their latest blog, Hanover Health’s Emma Eatwell and Josie Godfrey explore what the future for VBC might look like.

The future of nanomedicine regulation

With the EU’s upcoming revision of the general pharmaceutical legislation, the bloc has the chance to provide long-awaited clarity around the future of nanomedicine. And just as important, it will give the EU a chance to lead on a conversation around the needed regulatory framework for nanomedicines as other countries -including the US- currently struggle with this. In their latest blog, Hanover Brussels Alicia Rojo Santos and Pilar Serrano explores why the sector expecting to set off following the success of the Pfizer and Moderna SARS-CoV-2 vaccines is more important than ever.

Getting it Right First Time: Building a Value-Based Contract Strategy

In their latest blog, Hanover Brussels Emma Eatwell and Josie Godfrey will explore how companies can efficiently and effectively increase the chances of securing value-based contracts that work for all.

The role of pharma in breaking through the backlog

As health systems emerge from the pandemic, and attention turns to the backlog of patients waiting for treatment, how can the pharmaceutical industry position itself as part of the solution? In his latest blog, Hanover Health’s Alexander Davies looks to answer the following questions – big pharma was there for the world when it needed vaccines in record-breaking time, can it find the innovations that we need now to clear through the queue of people waiting for treatment? Can it partner with health systems to speed up access, improve patient outcomes and reduce the burden on healthcare professionals? And, if it did so, what are the opportunities for its reputation?

Cardiovascular disease: The scale of the challenge

Many years in the making, the first CVDPREVENT audit report, published recently, gives a detailed snapshot of how those with cardiovascular diseases (CVD) are identified, diagnosed, and managed across England. In his latest blog, Hanover Health’s Mark MacDonald asks – what does this data tell us about the impact CVD is having on our collective health, how much are health inequalities a factor, and where are the opportunities for the system to collectively do better to prevent disease, disability, and death?

Cancer: Beyond the Backlog

With the recent performance of Cancer Waiting Times the worst on record, and predictions of thousands of ‘missing’ cancer patients that have yet to enter the system, Hanover’s Health’s Emma Greenwood asks – how do we get back to that transformation agenda and move beyond the backlog?

2022: What next after digital transformation?

After the inevitable push into the virtual world amplified by COVID-19 and robust efforts in the name of digital transformation across the healthcare sector, 2022 is set to be the year of digital integration. We’re past tactical plans disguised as strategies and merely replicating content across channels. A new approach by the pharmaceutical industry is required to respond to the new digital world. Hanover’s Health’s Solveig Veerkamp explains how a truly hybrid, holistic approach is essential to respond to the most important health challenges to come.

What next for health? The weeks that have seen a whirlwind in Whitehall.

It won’t have escaped your attention that the debris from the PM’s recent reshuffle has left industry and policy makers with more questions than it has answers. This comes at a critical time for the healthcare system, particularly ahead of the winter period. ‘Levelling Up’ is the agenda. Covid has highlighted the extent of health inequalities across the UK. In her latest blog, Ursula Ritz considers the implications of the change of senior leadership at DHSC and NHSE for existing priorities, including for those of us committed to ensuring the best and innovative drugs make it to patients.

Will most electronic consumer goods turn into medical devices after the MDR?

In her latest blog, Hanover Brussels Aleksandra Lugovic explores concerns over the rising coexistence of health apps and electronic goods that may become medical devices according to the EU Regulation.

What do NHS changes and the Life Sciences Vision mean for medicines?

With the publication of the new Life Sciences Vision, a new NHS Bill, and new Health Secretary and NHS England Chief Executive, there are many fresh additions to add to the blur of change in the NHS. But what do they mean for medicines? In his latest blog, Hanover Health’s Andrew Harrison argues that there is a need for a renewed value story for medicines in the NHS, one which articulates their contribution to the prevention agenda and how they can relieve the burden of care on the health system.

Addressing the Gendered Health Data Gap
The Women’s Health Strategy for England presents an opportunity to ensure that gendered inequalities in health data are recognised and addressed. Caroline Cirado Perez’s ‘Invisible Women’ highlights how women are missing from data sets leading to health interventions and technologies designed for men as the default. For example, women are 50% more likely to be misdiagnosed following a heart attack because participation in clinical trials is generally skewed towards males. In her latest blog, Hanover Health’s Emma Gorton outlines why data should form a key part of the Women’s Health Strategy to help address inequalities in outcomes for women.
Greener healthcare - a shared challenge

At six months out from the COP26 UN climate summit in November, political leaders are focusing on industry to help cut emissions. In 2019 the NHS equated to ~5% of total UK carbon footprint, and it is now targeting 2045 net zero for itself and its wider footprint. The search for healthcare suppliers that meet these commitments by the end of the decade is on, and the time to act is now. In the pharmaceutical sector manufacturing sustainable plastic, hydrogen power, or green steel are all being debated – and healthcare companies will need cross-sector support in finding futureproofed solutions. In her latest blog, Hanover Health’s Alison Woodhouse considers the steps and collaboration that will be required in order for the NHS, and UK government, to meet their ambitious net zero targets.

Why it’s in everyone’s interest the Women’s Health Strategy for England succeeds

Timed to coincide with International Women’s Day, the Government’s Women’s Health Strategy for England landed at a moment of national contemplation about women’s place in society more generally, following the murder of Sarah Everard. In her latest blog, Hanover Health’s Jennifer Blainey breaks down the strategy and considers what needs to happen for it to succeed.

COVID-19 has changed the way we must talk about treatment for rare diseases

The turbulence of the last year has brought into sharp focus the difficult choices to be made when it comes to healthcare prioritisation. There is now more of a reluctant acceptance that there will always be someone or something that will miss out so the ‘unjust’ emotional argument won’t resonate in the same way anymore. In her latest blog, Hanover Health’s Emma Gorton considers why in the wake of Covid-19, communicators must change their narrative around the treatment of rare diseases.

What does the COVID-19 vaccine mean for the future of R&D?
Amid a pandemic, time is a luxury the world cannot afford. The last 12 months have contradicted what we once thought about the speed of progressing scientific research. Here Shannon Lacombe explores the factors that have contributed to the unprecedented speed of vaccine development from early-stage research to mass public rollout. She also looks at what precedent this has set for the future of research and development timelines and the assumptions and status quo that will now be challenged as a result.
Is the world ready for a COVID-19 vaccine?

At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more than 90% effective at preventing COVID-19 infection. Since then, other good news has followed, with collaborations, including Moderna and AstraZeneca, publishing similarly positive results. This is a phenomenal feat that would have been unimaginable just one year ago. But a vaccine is only as effective as its deployment and uptake. There should be no doubt that as soon as the first COVID-19 vaccine was approved, a very difficult logistics game ensued. The reality is that a COVID-19 vaccine will present a whole new unfamiliar set of operational challenges. There are currently more than 170 candidate vaccines in development, each with its own benefits and each with its own challenges. Here, we explore some of those challenges and reflect on what must be considered by health systems and governments to set us on track towards pandemic recovery.

It's out - so what?
The European Commission’s Pharmaceutical Strategy has been published and the Commission has presented its priorities for the coming years. The focus is on patient access to affordable treatments; ensuring and boosting the competitiveness of the European pharmaceutical sector and making sure that the EU will have a strong voice on global health and pharmaceutical policy. Stakeholders now need to make sure that their voices are heard and included in upcoming proposals and, eventually, in legislation. By Jenni Kortelainen, Hanover EU
Let's be ambitious for patients and life sciences investment in Global Britain

“Take up of new medicines in the UK continues to be slow by international standards”. Since this Pharmaceutical Industry Competitiveness Task Force report in 2005, there have been at least five UK life science strategies plus three PPRS or VPAS deals. All have promised to accelerate access of new medicines to patients. Sadly, 12 years on, the 2017 Life Sciences Industrial Strategy could only restate the challenge: “Evidence demonstrates that access to and diffusion of products in the NHS is often slower than in some comparable countries”. Can we ever break this cycle? By Andrew Harrison, Group Managing Director of Hanover Health.

What is everyone ‘ARPAing on about?

On Wednesday 16th September, Ursula Von Der Leyen, President of the European Union, announced in her State of Union address that they plan to develop BARDA, a Biomedical Advanced Research and Development Agency. This follows on from the Conservative Government pledging in their manifesto in late 2019 to develop ARPA, the Advanced Research Projects Agency. Both of these agencies are direct descendants of DARPA, the Defense Advanced Research Projects Agency founded in the USA in 1958 to create “Nation technology-based options for preventing – and creating - technological surprise.” Technological surprise is a wonderfully euphemistic phrase which refers to military “surprise” in the context of the Cold War. However, in the context of a global pandemic and the politicisation of the race to find a vaccine many are now drawing Cold War comparisons. But can DARPA, ARPA or BARDA actually deliver technological surprise? Jennifer Blainey, Director, Hanover Health explores.

Tackling obesity via green prescribing: A piece of cake or a half-baked strategy?

In our new article, Lloyd Tingley explores the wider societal and behavioural factors that will impact the success of green prescribing and the obesity strategy, and the role companies will play in driving a society wide approach that impacts infrastructure, adherence, health inequalities, and more.

EU Pharmaceutical Strategy Roadmap

As discussed in a recent article, the next few years will define the future of life sciences and especially the regulation of breakthrough advanced therapy medicinal products (ATMPs) and orphan medicinal products (OMPs) in the EU. Here Senior Healthcare Director Emma Eatwell examines the impact of the recently-published European Commission Roadmap to develop an EU Pharmaceutical Strategy and considers what the the future looks like for ATMPs and OMPs.

Does digital primary care offer a sustainable solution?
After years in which the local GP surgery seemed stuck in the digital doldrums, the last few months have seen a digital revolution sweep across GP practices, driven by the extraordinary circumstances of the Coronavirus. NHS digital figures show that in 2019 less than one in every 100 GP appointments were carried out by online video consultation, and nearly 4 in 10 people had no access to online consultations at all. In the space of two months this has shifted, with GPs having to adapt to a new way of working while tackling the demands of a new disease. What does this all mean for the future of primary care? By Jack Turner, Senior Account Director, Hanover Healthcare.
Global communications during and post a worldwide pandemic: how can organisations break through the noise?

COVID-19 has understandably dominated the news agenda like no other story in a generation. But what about other disease areas that are both important and deserve public attention? How do we break through this wall, particularly as coronavirus looks set to govern the news agenda for the next few months at least, if not longer?

War on drugs: the use of controlled substances in medicine

Infamously coined America’s ‘public enemy number one’ by President Nixon, are controlled substances a fundamental missing part of modern medicine? By Emma Gorton, Senior Director at Hanover Communications

L.E.A.D by example: the art of corporate storytelling

Alex Davies, Director at Hanover Health, considers the art of corporate storytelling and how we must challenge our clients to achieve a powerful narrative.

Addressing Climate Impact: The Healthcare Paradox

For the healthcare and pharmaceutical industry, the impact of climate change is twofold – responding to the increased risk of certain diseases and conditions and decarbonising their own processes and products to prevent worsening impact.

Hanover Health launches the Mackay Programme

New programme for communicators looking to breakthrough in their careers.

Latest Tweets

Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Address:
Riverside House
Southwark Bridge House
London
SE1 9HA
United Kingdom

Latest content on this profile

Will the NHS be safe in Liz Truss’s Hands?
As expected, Liz Truss has been anointed as the new Prime Minister. One of her major challenges is the NHS and, with only two years to another general election, she does not have much time to restore falling public confidence in the service.
Hanover Communications
A new prescription for the U.S. healthcare market?
Last month the U.S. Government passed the Inflation Reduction Act, paving the way for unprecedented drug pricing reforms across the country. In a market with spiralling healthcare costs, and increasing stories of patients missing out, or rationing treatment, the Act is welcomed by many. But it’s also severely criticised by others, including representatives from the pharmaceutical industry who say it jeopardises future innovation and drug discovery. As the largest pharmaceuticals market, the impact of the legislation will be felt outside of the U.S., but what does this look like, in the short and long-term? Is it a proverbial drop in the ocean, or is a storm brewing?
Hanover Communications
What's next for the 'indispensable' health system?
No one is remotely indispensable” – those of the words many of us have heard these past few weeks. As Boris Johnson and the previously incumbent Cabinet are now considering their next moves, where does that leave health policy at one of the most volatile points in recent history? We were set for a bumper few months of hotly anticipated announcements, including the 10-Year Cancer  Plan response, the Women’s Health Strategy, and the implementation plan for the Life Sciences Vision, amongst many others. But what will happen as the forthcoming leadership contest dominates the column inches? How will the Civil Service and NHS stand up to the challenges it faces without certainty of who is steering the ship? We will explore some of the possibilities of what will happen next, and most importantly, how we in communications can support the health system at such a critical time post-pandemic. To find out, read the latest blog on the PM Hub, penned by Hanover Health's Senior Account Director Ursula Ritz.
Hanover Communications
How can the UK be a catalyst for change in women’s health? 
Women’s health has once again been thrust to the fore, with almost daily stories on hormone replacement therapy (HRT) supply shortages in the UK providing us with a stark reminder of the challenges women are facing in this country every day. The good news is, the UK Government is making a genuine and concerted effort to tackle women’s health issues, having set out its Vision for women’s health in December, and a full Strategy due to be published imminently. We have a real opportunity to change women’s experience of healthcare for the better, but we cannot afford to get this wrong. In her latest blog, Hanover’s Georgia Hunt explores how the upcoming Women’s Health Strategy should address the concerns of women today and improve the lives of the women of tomorrow.
Hanover Communications
Innovative contracting at the top of the market access agenda
Value-based contracting (VBC) is firmly on the market access agenda across Europe and there are converging views on what is needed in this space.  Pharma and biotech, patients, payers, regulators and HTA agencies gathered at the World Evidence, Pricing and Access Congress in March to discuss challenges and potential solutions. Hanover hosted a discussion about experiences of VBC and where changes are needed. We explored whether a global archetype approach could support in-country negotiating agreements.   In their latest blog, Hanover Health’s Emma Eatwell and Josie Godfrey explore what the future for VBC might look like.
Hanover Communications
The future of nanomedicine regulation
With the EU’s upcoming revision of the general pharmaceutical legislation, the bloc has the chance to provide long-awaited clarity around the future of nanomedicine. And just as important, it will give the EU a chance to lead on a conversation around the needed regulatory framework for nanomedicines as other countries -including the US- currently struggle with this. In their latest blog, Hanover Brussels Alicia Rojo Santos and Pilar Serrano explores why the sector expecting to set off following the success of the Pfizer and Moderna SARS-CoV-2 vaccines is more important than ever.
Hanover Communications